Daily news on business and economy in Yemen
Provided by AGP
ZTS SHAREHOLDER INVESTIGATION: Levi & Korsinsky Investigates Zoetis for Possible Securities Law Violations
Zoetis guided investors to 3%-5% organic revenue growth for FY 2026 while internal data already pointed to deteriorating U.S. pet-care demand and a looming generic threat to its top-selling dermatology drug
NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Shareholders who held Zoetis Inc. (NYSE: ZTS) stock lost approximately 21.5% of their investment on May 7, 2026 -- roughly $23.91 per share in a single session -- after the company slashed FY 2026 revenue guidance it had affirmed just weeks earlier. Those who purchased ZTS shares and suffered losses are encouraged to submit their information to Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
On February 2, 2026, CEO Kristin Peck told investors Zoetis was "guiding to a range of 3% to 5% organic operational revenue growth" for FY 2026 and stated "these near-term dynamics are unfolding within a broader U.S. macro environment that we believe will gradually improve as we move through 2026." The company did not reference internal data indicating a significant slowdown in U.S. discretionary pet spending.
When Zoetis reported Q1 2026 results on May 7, 2026, it cut full year revenue guidance to a range of $9.68 billion to $9.96 billion, citing the same competitive pressures and macro headwinds that had been present months earlier. ZTS shares fell roughly 21.5% that day. The gap between the February guidance and the May revision spans substantial projected revenue -- a difference investors were not positioned to evaluate when the guidance was issued.
If you lost money on Zoetis stock, click here to discuss your legal rights with Levi & Korsinsky. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the ZTS Investigation
Q: How much did ZTS stock drop? A: Shares fell approximately 21.5% -- a decline of roughly $23.91 per share -- on May 7, 2026, after Zoetis slashed its FY 2026 revenue guidance. Investors who purchased shares before this disclosure may be eligible to participate in the investigation.
Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Zoetis made materially false or misleading statements regarding its FY 2026 revenue outlook, the competitive landscape for key products, and the sustainability of U.S. pet-care demand trends. When the company revised its guidance downward, the stock price declined sharply.
Q: What do ZTS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.
Q: What if I already sold my ZTS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ZTS and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What if I live outside the United States? A: U.S. securities fraud investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
